{"id":"NCT01294787","sponsor":"Novartis Pharmaceuticals","briefTitle":"Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 Âµg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2011-02-11","resultsPosted":"2013-03-20","lastUpdate":"2013-03-20"},"enrollment":85,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"indacaterol and glycopyrronium bromide (QVA149)","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]}],"arms":[{"label":"indacaterol and glycopyrronium bromide (QVA149)","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"tiotropium","type":"ACTIVE_COMPARATOR"}],"summary":"This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).","primaryOutcome":{"measure":"Exercise Tolerance Comparison Between QVA149 and Placebo Groups","timeFrame":"3 weeks","effectByArm":[{"arm":"QVA149","deltaMin":507.8,"sd":19.3},{"arm":"Placebo","deltaMin":448.3,"sd":19.49}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":13,"countries":["Germany","Spain"]},"refs":{"pmids":["24534204"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":77},"commonTop":["Chronic obstructive pulmonary disease","Cough"]}}